Skip to main content

Advertisement

Table 1 Posted results of monotherapy with pembrolizumab, atezolizumab, nivolumab, durvalumab and avelumab in advanced NSCLC

From: Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Identifier Trials Agent phase Indication Population Arms Biomarkers ORR mPFS mOS mDOR Adverse effects (grade ≥ 3)
NCT01295827 Keynote 001 Pembrolizumab I Second line Advanced NSCLC Pembrolizumab Regardless PD-L1 19.40% 3.7 m 12.0 m NR 9.50%
PD-L1 ≥ 50% 45.20% 6.3 m NR 12.5 m NA
NCT01905657 Keynote 010 Pembrolizumab II/III Second line Previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells Pembrolizumab = 2 mg/kg PD-L1 ≥ 50% 30.00% 5.0 m 14.9 m NR 13.00%
Pembrolizumab = 10 mg/kg PD-L1 ≥ 50% 29.00% 5.2 m 17.3 m NR 16.00%
Docetaxel PD-L1 ≥ 50% 8.00% 4.1 m 8.9 m 8 m 35.00%
NCT02142738 Keynote 024 Pembrolizumab III First line Previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no mutation of EGFR or ALK Pembrolizumab 200 mg/3 weeks PD-L1 ≥ 50% 44.80% 10.3 m NR NR 26.60%
Platinum-based chemotherapy 27.80% 6.0 m 14.5 m 6.3 m 53.30%
NCT02220894 Keynote 042 Pembrolizumab III First line Previously untreated advanced non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with ECOG 0 or 1, and a PD-L1 TPS of 1% or greater Pembrolizumab PD-L1 ≥ 50% 39.50% 7.1 m 20.0 m 20.2 m 17.80%
PD-L1 ≥ 20% 33.40% 6.2 m 17.7 m
PD-L1 ≥ 1% 27.30% 5.4 m 16.7 m
Platinum-based chemotherapy PD-L1 ≥ 50% 32.00% 6.4 m 12.1 m 10.8 m 41.90%
PD-L1 ≥ 20% 28.90% 6.6 m 13.0 m 8.3 m
PD-L1 ≥ 1% 26.50% 6.5 m 12.1 m 8.3 m
NCT02008227 OAK Atezolizumab III Second line Previously treated NSCLC Atezolizumab ITT population 14.00% 2.8 m 13.8 m 16.3 m 15.00%
Docetaxel 13.00% 4.0 m 9.6 m 6.2 m 43.00%
NCT01642004/NCT01673867 Checkmate 017/057 Nivolumab III Second line Previously treated patients with advanced squamous or nonsquamous non–small-cell lung cancer Nivolumab NA NA 2.56 m 11.1 m Squamous: 25.2 m 10.00%
Non-squamous: 17.2 m
Docetaxel NA 3.52 m 8.1 m Squamous: 8.4 m 55.00%
Non-squamous: 5.6 m
NCT01693562 Study 1108 Durvalumab I/II Second line Pretreated NSCLC EGFR/ALK wild type Durvalumab from 0.1 to 10 mg/kg q2w or 15 mg/kg q3w PD-L1 ≥ 25% 25.30% 2.8 m 15.4 m NR 10.00%
PD-L1<25% 6.10% 1.5 m 7.6 m
First line Treatmentnaïve advanced NSCLC EGFR/ALK wild type Durvalumab
10 mg/kg q2w
PD-L1 ≥ 25% 28.60% 4.0 m 21 m NR 9.00%
PD-L1<25% 11.00% NA NA
NCT02220894 ATLANTIC Durvalumab II Third line Heavily pretreated advanced NSCLC EGFR/ALK positive Durvalumab PD-L1 ≥ 25% 14.10% 1.9 m 13.3 m 7.4 m 5.40%
PD-L1<25% 3.60% 1.9 m 9.9 m NR  
Heavily pretreated advanced NSCLC EGFR/ALK wild type or unknown Durvalumab PD-L1 ≥ 90% 30.90% 2.4 m NR NR 17.60%
PD-L1 ≥ 25% 7.50% 3.3 m 10.9 m 8.20%
PD-L1<25% 3.30% 1.9 m 9.3 m
NCT02766335 Lung-Map Durvalumab II Second line Pretreated NSCLC EGFR/ALK wild type Durvalumab PD-L1 ≥ 25% 14.30% NA 10.7 m NR 34.00%
PD-L1<25% 6.90% NA 11.6 m
Docetaxel NA 6.70% NA 7.7 m NR NA
NCT02125461 PACIFIC Durvalumab III Second line Unresectable stage III NSCLC after chemoradiation Regardless of PD-L1 status Durvalumab NA 28.40% 16.8 m 23.2 m NR 29.90%
Placebo 16.00% 5.6 m 14.6 m 26.10%
NCT02395172 JAVELIN Lung 200 Avelumab III Second line Platinum-treated patients with advanced NSCLC Avelumab PD-L1 ≥ 1% 19.00% 3.4 m 11.4 m NR 10.00%
  1. Patients can obtain survival and life quality benefits from monotherapy with tolerable adverse reactions
  2. ORR objective response rate, mPFS median Progression Free Survival, mOS median Overall survival, mDOR median Duration of Response, NR not reached, NA nona, ITT intend to treat